133 related articles for article (PubMed ID: 37804814)
1. Development and in vitro evaluation of carmustine delivery platform: A hypoxia-sensitive anti-drug resistant nanomicelle with BBB penetrating ability.
Li D; Ren T; Wang X; Xiao Z; Sun G; Zhang N; Zhao L; Zhong R
Biomed Pharmacother; 2023 Nov; 167():115631. PubMed ID: 37804814
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia and CD44 receptors dual-targeted nano-micelles with AGT-inhibitory activity for the targeting delivery of carmustine.
Li D; Wang X; Han K; Sun Y; Ren T; Sun G; Zhang N; Zhao L; Zhong R
Int J Biol Macromol; 2023 Aug; 246():125657. PubMed ID: 37399878
[TBL] [Abstract][Full Text] [Related]
3. A multi-functional hypoxia/esterase dual stimulus responsive and hyaluronic acid-based nanomicelle for targeting delivery of chloroethylnitrosouea.
Li D; Ren T; Ge Y; Wang X; Sun G; Zhang N; Zhao L; Zhong R
J Nanobiotechnology; 2023 Aug; 21(1):291. PubMed ID: 37612719
[TBL] [Abstract][Full Text] [Related]
4. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
5. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
7. The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.
Sarkar A; Dolan ME; Gonzalez GG; Marton LJ; Pegg AE; Deen DF
Cancer Chemother Pharmacol; 1993; 32(6):477-81. PubMed ID: 8258197
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Wedge SR; Porteus JK; May BL; Newlands ES
Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
[TBL] [Abstract][Full Text] [Related]
10. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Bacolod MD; Johnson SP; Pegg AE; Dolan ME; Moschel RC; Bullock NS; Fang Q; Colvin OM; Modrich P; Bigner DD; Friedman HS
Mol Cancer Ther; 2004 Sep; 3(9):1127-35. PubMed ID: 15367707
[TBL] [Abstract][Full Text] [Related]
11. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
12. Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
Qian L; Zheng J; Wang K; Tang Y; Zhang X; Zhang H; Huang F; Pei Y; Jiang Y
Biomaterials; 2013 Nov; 34(35):8968-78. PubMed ID: 23953782
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
[TBL] [Abstract][Full Text] [Related]
14. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer.
Phillips WP; Gerson SL
Cancer Chemother Pharmacol; 1999; 44(4):319-26. PubMed ID: 10447580
[TBL] [Abstract][Full Text] [Related]
16. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
17. iRGD-mediated core-shell nanoparticles loading carmustine and O
Liu C; Yao S; Li X; Wang F; Jiang Y
J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474
[TBL] [Abstract][Full Text] [Related]
18. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
19. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Wedge SR; Newlands ES
Br J Cancer; 1996 May; 73(9):1049-52. PubMed ID: 8624262
[TBL] [Abstract][Full Text] [Related]
20. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
Lee K; Gerson SL; Maitra B; Koç ON
J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]